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OBJECTIVES We assessed the operative and late mortality and the present clinical status of 216 patients
with tricuspid atresia who had a nonfenestrated Fontan procedure performed at the Mayo
Clinic in the 25-year period 1973 to 1998.
BACKGROUND The Fontan operation eliminates the systemic hypoxemia and ventricular volume overload
characteristic of prior forms of palliation. However, it originally did so at the cost of systemic
venous and right atrial hypertension, and the long-term effects of this “price” were unknown
when the procedure was initially proposed.
METHODS We reviewed the clinical records of the 216 patients retrospectively. These were arbitrarily
grouped into early (1973 through 1980), middle (1981 through 1987) and late (1988 through
1997) surgical eras. Patient outcome was also analyzed according to age at surgery. Operative
and late mortality rates were determined and present clinical status was ascertained in 167 of
171 surviving patients.
RESULTS Overall survival was 79%. Operative mortality steadily declined and was 2% (one of 58
patients) during the most recent decade. Late survival also continues to improve. Age at
operation had no effect on operative mortality, and late mortality was significantly increased
only in patients who were operated on at age 18 years or older. Eighty-nine percent of
surviving patients are currently in New York Heart Association class I or II.
CONCLUSIONS The initial 25-year experience with the nonfenestrated Fontan procedure for tricuspid atresia
has been gratifying, with most survivors now leading lives of good quality into adulthood.
These results justify continued application of this procedure for children born with tricuspid
atresia. (J Am Coll Cardiol 2001;37:933–9) © 2001 by the American College of Cardiology
The first nonfenestrated Fontan operation at the Mayo
Clinic was performed in March 1973 on an adult with
tricuspid atresia, and through January 1, 1998, a total of 216
nonfenestrated Fontan procedures had been carried out for
patients with tricuspid atresia; 182 of these patients had
normally related great arteries and 34 had associated trans-
position of the great arteries.
Early and late results from this series of 216 patients with
tricuspid atresia were reviewed. The current status of sur-
viving patients was ascertained by direct examination, chart
review, questionnaire or telephone contact. Of the 171
patients still alive, present clinical status could not be
accurately determined in only four, all of whom live outside
the U.S. However, all four of these patients were known to
be alive no more than 12 months previously. Follow-up of
survivors now ranges from 1 to 24 years, with a median of
13 years.
METHODS
Era of operation. We arbitrarily divided the 25-year expe-
rience into an early period, 1973 through 1980; a middle
period, 1981 through 1987; and the most recent 10-year
experience, 1988 through 1997. These groups comprised
54, 104 and 58 patients, respectively.
Age at operation and prior palliation. The patients’ ages
at which the Fontan procedure was performed are listed in
Table 1. Because the vast majority of patients were beyond
early childhood, all but 17 had undergone at least one prior
palliative cardiovascular operation (Table 1). The frequency
and type of previous palliative operations are listed in Table 2.
Modifications of surgical technique. Modifications in
surgical technique for the Fontan operation have evolved
with experience. In the early cases, the atrial septal defect
was closed by direct suture or patch. Five patients, all
operated on before 1978, had a porcine glutaraldehyde-
preserved heterograft valve placed at the inferior vena
cava-right atrial junction, a practice that was abandoned
when it was learned that these valves degenerate and
become nonfunctional and often obstructed. The type of
connection used to direct systemic venous blood to the
pulmonary arteries (PAs) in these patients is listed in Table
2. The use of valved conduits was also characteristic of the
early experience; all four of the right atrium-to-PA valved
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conduits and 16 of the 27 right atrium-to-hypoplastic right
ventricle valved conduits were placed before 1981. In the
middle period, the method of choice for directing systemic
venous blood to the PAs was direct anastomosis of the right
atrium or right atrial appendage to the right or main PA.
Beginning in early 1989 and continuing to the present,
alternative approaches have included a lateral tunnel com-
bined with either an atriopulmonary or a bidirectional
cavopulmonary anastomosis, or an extracardiac nonvalved
conduit combined with a bidirectional cavopulmonary anas-
tomosis.
Concomitant surgical procedures. Additional procedures
carried out at the time of the Fontan procedure included
mitral valve repair in six patients and mitral valve replace-
ment in six additional patients, all of whom had moderate or
severe mitral valve incompetence. In three of the valve
replacements, a heterograft valve (Hancock) was inserted; in
the others a mechanical valve was used. Twenty-six patients
underwent varying degrees of PA reconstruction, usually to
alleviate narrowing and distortion caused by a prior shunt.
Two patients, one with a prior Waterston shunt and one
with a prior Potts shunt performed during early infancy, had
iatrogenic complete occlusion of the left PA with some
secondary hyperplasia of the right PA. In these two patients,
the Fontan procedure was carried out to the single right PA.
The cumulative probability of patient survival was esti-
mated as a function of time since surgery by the Kaplan-
Meier method. Ninety-five percent confidence levels were
calculated for patient survival at five-year intervals and
plotted on the survival curves. The effects of risk factors,
such as era of surgery and patient age group, on cumulative
patient survival were assessed with log-rank tests.
RESULTS
Operative and late mortality. Figure 1 is a Kaplan-Meier
survival curve for the entire group of 216 patients. Opera-
tive, late and overall mortality rates for the patients operated
on during the early, middle and most recent periods are
shown in Table 3. There has been a steady, significant
reduction in operative mortality, from 17% in the early
period to 9% in the middle period, and 2% during the most
recent decade (p value ,0.01, exact Wilcoxon rank sum
test). Late survival also continues to improve significantly as
demonstrated in Figure 2, where Kaplan-Meier survival
curves demonstrate continued survival rates for the 197
operative survivors during the three periods.
Causes of late death. Twenty-six late deaths occurred,
ranging from four months to 18 years after operation
(median 8 years). Seven deaths were sudden and unex-
pected, presumably a result of dysrhythmia, inasmuch as
postmortem examination showed no other cause of death.
Three of these patients had a history of post-Fontan rhythm
problems and were receiving antidysrhythmic medication at
the time of death. The four other patients did not have
postoperative disturbances in rhythm. Four late deaths were
attributed to progressive myocardial deterioration and fail-
ure. Two of these four patients were adults, ages 25 and 34
years at the time of their Fontan operation, who died 18 and
12 years, respectively, after operation, at ages 43 and 46
years. Three patients died at the time of reoperation: one for
mitral valve replacement, one for resection of subaortic
obstruction, and one at the time of attempted cardiac
transplantation at another institution. Three late deaths
were believed to be thromboembolic in nature. The deaths
in these three patients, all of whom had postmortem
examinations, were attributed to a large pulmonary embolus
in one, thrombosis of a right atrial to right ventricular (RV)
Hancock conduit in another and Budd-Chiari syndrome
caused by hepatic vein thrombosis in the third. Three other
late deaths were due to the debilitating effects of chronic
protein-losing enteropathy. These three deaths occurred six,
13 and 15 years after operation, and the time from recog-
nition of the protein-losing enteropathy until death was
two, five, and six years, respectively.
Of the six remaining late deaths, two were accidental (a
motorcycle and an automobile accident). Two relatively
early late deaths, four and six months postoperatively, were
attributed to persistent pleural effusions in one case and to
chronic respiratory insufficiency in the second. The causes of
the remaining two late deaths, in which no postmortem
examination was performed, could not be conclusively
determined.
Effect of operative age on survival. The effect of age at the
time of the Fontan operation on early and late survival was
also analyzed (Fig. 3). There was no statistically significant
difference in operative mortality. Although there is a trend
toward improved survival in patients who had their Fontan
operation at younger ages, it does not reach statistical
Table 1. Age at Operation and Previous Palliative Operations
Age at
Operation
(yr)
No. of
Patients
No. of Previous
Cardiovascular Surgical
Procedures
No. of
Patients
,2 9 0 17
2–3 27 1 118
4–6 53 2 64
7–10 44 3 16
11–15 37 4 1
16–19 21 Total 216
20–30 18
31–40 6
.40 1
Total 216*
*Range 7 months to 42 years; median 8 years.
Abbreviations and Acronyms
LV 5 left ventricular
NYHA 5 New York Heart Association
PA 5 pulmonary artery
RA 5 right atrium
RV 5 right ventricle, right ventricular
934 Mair et al. JACC Vol. 37, No. 3, 2001
Early and Late Results With Fontan Procedure March 1, 2001:933–9
significance. Only in patients who had their Fontan proce-
dure as adults age 18 or older is a clear pattern of
significantly decreased late survival beginning to emerge.
This pattern does not reach statistical significance until
more than 15 years after the operation.
Incidence of reoperation in current survivors. One hun-
dred seventy-one patients survived. In this group, 24 pa-
tients have had 26 reoperations, two patients having had
two separate reoperations. Six reoperations involved re-
placement of the valved conduit with a new valved conduit;
these occurred in the 1970s and early 1980s before the use
of such conduits was abandoned. Nine reoperations were
performed for removal of a valved conduit and conversion to
an atriopulmonary anastomosis. Two reoperations, both in
the 1970s, were for closure of a recurrent atrial septal defect.
Three operations were pericardiectomy procedures carried
out because of recurrent pericardial effusion. Two reopera-
tions were successful cardiac transplantations in patients
who were doing poorly because of gradual myocardial
deterioration. Two patients had conversion of their original
atriopulmonary anastomosis to a lateral tunnel type of
Fontan procedure. The remaining two reoperations were: 1)
a repeat pulmonary artery angioplasty in a patient who
experienced recurrent left PA stenosis in the era before
balloon angioplasty and stenting were available, and 2)
resection of subaortic stenosis in a patient originally having
had tricuspid atresia and associated transposition of the
great arteries.
Additional procedures for the treatment of dysrhythmias.
Among the 171 surviving patients, 11 required additional
procedures to treat symptomatic dysrhythmias. Eight had
insertion of a permanent pacemaker, four because of brady-
cardia and four because of paroxysmal tachycardia. Three
patients had catheter ablation of an accessory pathway or
ectopic focus to eliminate paroxysmal atrial tachycardia.
Current clinical status of survivors. The length of post-
operative follow-up and the present ages of surviving pa-
tients are shown in Table 4. We could ascertain the current
clinical status in 167 patients. One hundred forty-nine
patients, 89% of those responding, were in New York Heart
Association (NYHA) class I or II and were either full-time
students or were employed full time or capable of full-time
work. Eighteen patients (11%) were judged to be in NYHA
class III or IV, with significant symptoms or disability. The
problems that these 18 patients were experiencing included
recurrent and refractory atrial dysrhythmias, protein-losing
enteropathy, congestive heart failure due to deterioration of
left ventricular (LV) function and, in one patient, sequelae
from a post-Fontan stroke.
DISCUSSION
Fontan performed the first successful right heart bypass on
a patient with tricuspid atresia in 1969 (1). It was designed
to completely separate the systemic and pulmonary circula-
tions and thereby to eliminate the systemic arterial hypox-
emia and LV volume overload that are the hallmarks of this
condition. It was recognized at the onset, however, that the
Figure 1. Kaplan-Meier curve for cumulative survival of the total 216
patients. The median postoperative follow-up period is 13 years and 79%
of the patients survive.
Table 2. Type of Previous Palliation and Systemic Venous-to-Pulmonary Connection
Type of Previous Palliative Procedure
No. of
Patients Type of Connection*
No. of
Patients
Blalock-Taussig (classic or modified) 141 RA to RV valved conduit 27
Waterston 44 RA to PA valved conduit 4
Classic Glenn 39 RA to RV direct anastomosis 35
Pulmonary artery banding 30 RA to PA direct anastomosis
(with or without lateral tunnel)
146
Potts 15 Total cavopulmonary connection 2
Blalock-Hanlon 7 Extracardiac nonvalved conduit 2
Central shunt 9 Total 216
Bidirectional cavopulmonary anastomosis 6
Other 7
Total 298
*RA 5 right atrium; RV 5 right ventricle; PA 5 pulmonary artery.
Table 3. Operative and Late Mortality by Era of Operation
Years of
Operation
No. of
Patients
Deaths (no.) Deaths (%)
Operative Late Operative Overall
1973–1980 54 9 14 17 43
1981–1987 104 9 10 9 18
1988–1997 58 1 2 2 5
Total 216 19 26 9 21
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elevated systemic venous pressures inevitably present after
the Fontan procedure—necessary to propel the blood
through the lungs in the absence of a “booster pump” on the
right side of the circulation—might lead to late complica-
tions in surgical survivors. Also, functional limitations
would likely still exist in these patients, particularly for
physical activities that required a substantial increase in
cardiac output.
More than 30 years have passed since Fontan’s original
surgical procedure, and it has undergone many technical
modifications, an evolution that still continues. This Mayo
Clinic series encompasses 25 years and many of the surgical
survivors have reached adulthood. It has been 10 years since
we last reported our early and late results with the Fontan
procedure for tricuspid atresia (2). We are therefore now in
a better position to assess what has been accomplished by
this novel surgical approach and to make recommendations
concerning its continued application.
Selection criteria for the Fontan procedure. Choussat
and Fontan and other colleagues (3) originally listed “ten
anatomic and physiologic commandments” that they be-
lieved must be met before this new operative approach could
be successfully applied. Over time, it has become clear that
the most important criteria involve the size of the PAs, the
level of pulmonary arteriolar resistance and the status of
systolic and diastolic function of the patient’s single func-
tional ventricle. As experience with the procedure increased,
institutions with a large and ongoing patient population
have established and published modifications of the original
criteria in these areas, and well-recognized guidelines for
patient selection now exist (2,4).
Evolution of surgical techniques. Fontan advocated plac-
ing caval valves and using a valved right atrium-to-
hypoplastic RV conduit in his surgical patients with tricus-
pid atresia. It subsequently became clear that the caval valves
do not function well and often deteriorate rapidly and that
a hypoplastic RV was not necessary to propel the systemic
venous blood into the lungs. An experimental model in the
late 1980s (5) demonstrated that flow turbulence and kinetic
energy losses are reduced when pulsation in a valveless
chamber is eliminated and flow pathways are streamlined
Figure 2. Kaplan-Meier curves for cumulative continued survival of the
197 operative survivors divided into era of surgery: 1973 through 1980
(solid line), 1981 through 1987 (dotted line), 1988 through 1997 (dashed
line). There is a statistically significant improvement in continued survival
among patients operated on more recently.
Figure 3. Kaplan-Meier curves for cumulative survival of the 216 patients according to age at the Fontan procedure. There is no significant difference in
operative mortality. There is a trend toward improved continued survival in patients operated on at younger ages, but it does not reach statistical significance
in patients operated on before age 18 years.
Table 4. Length of Follow-up and Present Age of 171
Surviving Patients
Length of
Follow-up (yr)
No. of
Patients
Present
Age (yr)
No. of
Patients
0–5 5 0–10 17
6–10 50 11–20 57
11–15 54 21–30 60
16–20 52 31–40 30
21–25 10 41–50 6
.50 1
Total 171* Total 171†
*Range, 1–24 years; median, 13 years. †Range, 6–58 years; median, 22 years.
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maximally with the elimination of corners. This study
proposed total cavopulmonary connections with exclusion of
most of the right atrium (RA), a concept that, it was
thought, might reduce the incidence of postoperative atrial
dysrhythmias as well as improve hemodynamics. In recent
years, this concept has gained wide favor, and today in most
major centers the inferior vena caval flow is routed by a
lateral tunnel baffle within the right atrium to either a
bidirectional cavopulmonary anastomosis (6) or an atriopul-
monary connection, or via an entirely extracardiac pathway
(7), with the medial aspect of this pathway located along the
lateral border of the right atrium. There are still two
controversial questions. One is whether to “fenestrate” (8)
the inferior vena cava pathway. The other is whether it is
necessary to “stage” the Fontan procedure by performing a
bidirectional superior vena cava-to-PA anastomosis as a
preliminary operation before completing the Fontan circu-
lation by directing inferior vena caval blood directly to the
PAs as a “second stage” (9). Some institutions (10) have
favored these approaches in an attempt to decrease operative
mortality. At the Mayo Clinic, however, we continue to
favor the nonfenestrated, nonstaged approach in low-risk
surgical candidates. Our series had 39 patients who had
received a prior classic Glenn anastomosis and therefore
could be considered staged. The early and late mortality in
this subgroup did not differ significantly from the results in
the remaining 177 nonstaged patients. We reserve fenestra-
tion and/or staging for patients whose operative risk is
somewhat increased as a result of compromised ventricular
function, borderline-sized PAs or mildly elevated pulmo-
nary arteriolar resistance, or for patients who may require
concomitant atrioventricular valve repair or replacement or
subaortic resection at the time of their Fontan procedure.
Steady significant decrease in operative mortality. With
this approach, the operative mortality for the nonfenestrated
Fontan procedure for tricuspid atresia over the past decade
has been 2% (one death in 58 patients). The steadily
decreasing surgical mortality exhibited over the initial 25-
year experience has resulted from better patient selection,
improved surgical techniques and advances in immediate
postoperative intensive care management. In reviewing sur-
gical deaths from patients operated on during the 1970s and
early 1980s, it is clear that a number of these patients—
nearly all of whom had significant symptoms and for whom
there were no other therapeutic options in an era before
cardiac transplantation was well established—would not be
accepted as Fontan candidates today.
Age at operation today. Now that the Fontan procedure is
being performed electively in early childhood, usually at ages
2 to 4 years, the group reported here is clearly unique and
will not be duplicated, because many of these patients were
adolescents or even adults when they had their Fontan
procedure. Follow-up to date indicates that good early and
late results can be achieved in properly selected patients up
through at least the adolescent years. However, one could
reasonably expect that the operative and long-term late
results obtained in the preschool-aged children now under-
going the procedure will continue to improve. Although the
results obtained in this unique older group are generally
good, many of these patients endured years of systemic
hypoxemia and volume overload, with their potential detri-
mental long-term effects on ventricular function, before
their Fontan procedure.
Postoperative cardiac dysrhythmia. Because the Fontan
procedure as originally performed involved multiple suture
lines within the atrium and exposed the entire RA to
increased pressure and wall tension after completion, it was
recognized that postoperative atrial dysrhythmias might be
a concern. Follow-up studies (11–13) have established that
as many as 10% to 20% of Fontan patients may have
paroxysmal atrial tachycardia or atrial flutter-fibrillation. At
the recent follow-up of this series, eight patients were
receiving antidysrhythmic medication. Five patients were
very well controlled on their medical program whereas three
continued to have periodic episodes of symptomatic atrial
dysrhythmias. Although the rhythm disturbances are usually
amenable to medical therapy, in occasional instances they
may be refractory to drug therapy and require more aggres-
sive treatment, such as overdrive pacing or a surgical
intervention like the maze procedure (14). However, the
evolution of newer surgical techniques for the Fontan
operation such as the “extracardiac Fontan,” in which the
right atrium does not have multiple suture lines and also
does not have large portions of its wall exposed to increased
wall tension, offers promise for a reduced incidence of
troublesome atrial dysrhythmias in future operative survi-
vors (15).
Potential for late thromboembolic complications. The
potential for right heart thromboembolism in the postop-
erative Fontan patient is of concern because of the nonpul-
satile nature of the circulation and the decreased cardiac
output these patients may manifest. As previously outlined,
three patients in this series died of thromboembolic com-
plications. One presently surviving patient is moderately
disabled as a result of a post-Fontan stroke, presumably
caused by a cerebral embolus originating in the left heart. In
our 167 surviving patients on whom follow-up was ob-
tained, only eight were receiving any type of anticoagulation
therapy. These patients were all receiving warfarin, three
because of a mechanical prosthetic mitral valve and five,
with a history of atrial dysrhythmias, as thrombogenic
prophylaxis. The decision whether to routinely give the
post-Fontan patient long-term warfarin anticoagulant ther-
apy because of the potential for thromboembolism remains
controversial, but it has not been our policy to do so. Again,
with the new surgical techniques that “streamline” the flow
of blood through the right atrium and decrease the right
atrial volume, it is hoped that the potential for thrombus
formation may be reduced.
Protein-losing enteropathy as a late complication. With
the elevation of systemic venous pressure as an inevitable
consequence of the Fontan procedure, it was realized that
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protein-losing enteropathy might develop, a complication
seen previously in patients with constrictive pericarditis and
secondarily elevated systemic venous pressures. Three of the
late deaths in this series were clearly a result of this
complication. Only two of the survivors in our series are
presently requiring therapy for symptomatic protein-losing
enteropathy. One has become asymptomatic, with normal-
ization of serum albumin, on daily subcutaneous heparin
therapy; the second has had symptomatic improvement on
heparin therapy but continues to have slightly subnormal
serum albumin levels. A recent review from our institution
(16) revealed that the risk of development of protein-losing
enteropathy was 13.4% after 10 years. Although in an
appreciable number of patients the enteropathy may be mild
and remain asymptomatic, in others it may produce varying
degrees of hypoalbuminemia, with secondary pleural effu-
sions, ascites and so on. Medical therapy with anticongestive
measures and albumin infusion may benefit some symptom-
atic patients. In our experience, corticosteroids, as advocated
by some (17), have not been beneficial. Fenestration of the
atrial baffle, either surgically or in the catheterization labo-
ratory—which reduces RA pressure and increases cardiac
output, although at the expense of some arterial hypox-
emia—has reportedly (18) improved or eliminated protein-
losing enteropathy. Recently, the use of daily subcutaneous
heparin has been advocated (19,20). On occasion, when the
patient’s disorder is refractory to all other measures and is
continuing to deteriorate, cardiac transplantation is consid-
ered and has been successful in reversing this debilitating
and potentially fatal complication in some but not all
patients (21).
Advisability of pregnancy in adult women. As many
female Fontan patients reach adulthood, a frequent question
is the advisability of pregnancy. Four of the adult female
survivors in this series have had one successful full-term
pregnancy each. In each instance, the pregnancy and deliv-
ery were uncomplicated, the child had no congenital anom-
alies and the mothers felt their postpartum state of health
was unchanged from their status before pregnancy. There
were four known spontaneous miscarriages in our follow-up
group, three in one woman with no successful pregnancies
and one in one of the women who also had a successful
pregnancy. We have surveyed the adult female post-Fontan
population in an attempt to determine pregnancy outcome
(22). Although these patients did seem to have an increased
incidence (33%) of spontaneous first-trimester miscarriage,
in those who did not miscarry there were 15 live births from
14 different mothers. Only one child was born considerably
prematurely, and all 15 infants, including the premature
baby, are doing well. The only congenital heart disease in
the offspring was a case of secundum atrial septal defect. In
addition, all of the 14 mothers, including the one who had
two children, seemed to tolerate their pregnancies well, had
no special problems at the time of delivery and believe that
their postpartum state of health was not compromised in
comparison with their antepartum condition. Thus, al-
though this series is small, we concluded that women with
a good clinical result who want to have a child have a good
chance of a successful pregnancy without putting themselves
at substantial risk. Clearly, however, these women should be
made aware of the potential hazards of pregnancy, and if
they do become pregnant the pregnancy should be managed
in a facility with a “high-risk” obstetric unit.
Conclusions. Before the Fontan approach was devised,
patients with tricuspid atresia had a natural history charac-
terized by gradually increasing disability due to progressive
hypoxemia and ventricular myocardial deterioration. In
patients who did survive the childhood years, their quality of
life was usually substantially impaired by the time of
adolescence, and survival beyond early adulthood was un-
common (23). The initial 25-year experience with the
Fontan procedure at this institution has generally been
gratifying. Well-established selection criteria have evolved,
and for such properly selected patients the operative risk is
now 2%. Although follow-up reveals a significant late
mortality and morbidity, surgical advances and the current
tendency to perform the operation earlier in life (24), before
serious ventricular impairment has occurred, allow us to be
optimistic that these problems will become less prevalent.
Of the surviving 167 patients in this series on whom
follow-up information was available, most of whom are
adults, 89% were in NYHA class I or II, capable of full-time
school or employment and leading lives of good quality.
Clearly, additional time must pass before firm conclusions
can be drawn regarding the benefits of this palliative
approach for a congenital heart lesion for which correction
is not possible. However, this initial 25-year experience
suggests that the Fontan procedure has been a major step
forward in providing help and hope to patients with
tricuspid atresia, and that the children currently undergoing
the procedure have an excellent chance of surviving the
operation and leading good-quality lives well into their adult
years.
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